Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: December 28, 2022 Report Code: GDGMDHC22457IDB-ST

Select Item

Glioblastoma Multiforme Pipeline Drugs Market

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy.

The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under development for GBM, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for GBM and features dormant and discontinued projects.

GBM Pipeline Drugs Market Segmentation by Targets

Some of the targets in the GBM pipeline are Cells Expressing Epidermal Growth Factor Receptor, DNA, Epidermal Growth Factor Receptor, and Cells Expressing Interleukin 13 Receptor Subunit Alpha 2  among others. Cells Expressing Epidermal Growth Factor Receptor was the largest target in the pipeline.

GBM Pipeline Drugs Market Analysis, by Targets

GBM Pipeline Drugs Market Analysis, by TargetsFor more GBM pipeline drugs market target insights, download a free report sample

GBM Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the mechanisms of action in the GBM pipeline drugs market are Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, DNA Synthesis Inhibitor, Cytotoxic To Cells Expressing Interleukin 13 Receptor Subunit Alpha 2, and Programmed Cell Death Protein 1 Antagonist among others. Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor was the leading MoA in the pipeline.

GBM Pipeline Drugs Market Analysis, by Mechanisms of Action

GBM Pipeline Drugs Market Analysis, by Mechanisms of ActionFor more MoA insights into the GBM pipeline drugs market, download a free report sample

GBM Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the GBM pipeline drugs market are oral, intravenous, intratumor, and intradermal among others. The majority of the pipeline drugs followed the oral route of administration.

GBM Pipeline Drugs Market Analysis, by Routes of Administration

GBM Pipeline Drugs Market Analysis, by Routes of AdministrationFor more routes of administration insights into the GBM pipeline drugs market, download a free report sample

GBM Pipeline Drugs Market Segmentation by Molecule Types

The leading molecule types in the GBM pipeline drugs market are small molecule, monoclonal antibody, gene-modified cell therapy, and cell therapy among others. Small molecule was the leading molecule type in the pipeline.

GBM Pipeline Drugs Market Analysis, by Molecule Types

GBM Pipeline Drugs Market Analysis, by Molecule TypesFor more molecule type insights into the GBM pipeline drugs market, download a free report sample

GBM Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the GBM pipeline drugs market are Bristol-Myers Squibb Co, Novartis AG, Merck & Co Inc, Pfizer Inc, and Immunomic Therapeutics Inc among others. Among these, Bristol-Myers Squibb Co had the most number of products under development in 2022.

GBM Pipeline Drugs Market Analysis by Key Companies

GBM Pipeline Drugs Market Analysis by Key Companies

To know more about the GBM pipeline drugs market companies, download a free report sample

GBM Pipeline Drugs Market Report Overview

Key Targets Cells Expressing Epidermal Growth Factor Receptor, DNA, Epidermal Growth Factor Receptor, and Cells Expressing Interleukin 13 Receptor Subunit Alpha 2
Key Mechanism of Actions Cytotoxic to Cells Expressing Epidermal Growth Factor Receptor, DNA Synthesis Inhibitor, Cytotoxic to Cells Expressing Interleukin 13 Receptor Subunit Alpha 2, and Programmed Cell Death Protein 1 Antagonist
Key Routes of Administration Oral, Intravenous, Intratumor, and Intradermal
Key Molecule Types Small Molecule, Monoclonal Antibody, Gene-Modified Cell Therapy, and Cell Therapy
Key Companies Bristol-Myers Squibb Co, Novartis AG, Merck & Co Inc, Pfizer Inc, and Immunomic Therapeutics Inc

Scope

  • The report provides a snapshot of the global therapeutic landscape of GBM

  • The report reviews pipeline therapeutics for GBM by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in GBM therapeutics and enlists all their major and minor projects

  • The report assesses GBM therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews the latest news related to pipeline therapeutics for GBM

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for GBM (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding GBM (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

1st Bio Therapeutics Inc
4D Pharma Plc
A. Menarini Industrie Farmaceutiche Riunite Srl
Aadi Bioscience Inc
AB Pharma Ltd
AbbVie Inc
Ability Pharmaceuticals SL
ABM Therapeutics Inc
Accendatech Co Ltd
Acomhal Research Inc
Actuate Therapeutics Inc
Acura Nanomedicine Inc
ADCendo ApS
Adlai Nortye Biopharma Co Ltd
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
Adze Biotechnology Inc
Aettis Inc
Affimed GmbH
Agenus Inc
AiVita Biomedical Inc
Akeso Inc
Alaunos Therapeutics Inc
Alphageneron-Pharmaceuticals Inc
Alterity Therapeutics Ltd
Amal Therapeutics SA
Amasa Technologies Inc
Ambrx Biopharma Inc
Anagenics Ltd
Annji Pharmaceutical Co Ltd
Apac Biotech Pvt Ltd
Apexigen Inc
APIM Therapeutics AS
Apmonia Therapeutics SAS
Apogenix AG
Apollomics Inc
Aptamer Sciences Inc
Arcus Biosciences Inc
Argonaut Therapeutics Ltd
Arrien Pharmaceuticals LLC
Arrogene Inc
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Athenex Inc
Aucentra Therapeutics Pty Ltd
AUM Biosciences Pte Ltd
Avalia Immunotherapies Ltd
Avesthagen Ltd
Aveta Biomics Inc
Baobab AiBIO Co Ltd
Bayer AG
Beactica Therapeutics AB
BeiGene Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
Bellicum Pharmaceuticals Inc
BenevolentAI Ltd
Berg LLC
BerGenBio ASA
Beta Pharma Inc
Bexion Pharmaceuticals LLC
BeyondBio Inc
Bicara Therapeutics Inc
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
Bioasis Technologies Inc
BioEclipse Therapeutics Inc
BioIntegrator
BioNTech SE
Biorchestra Co Ltd
Biovista Inc
BioXpress Therapeutics SA
Black Diamond Therapeutics Inc
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
BoYuan RunSheng Pharma Hangzhou Co Ltd
Breakpoint Therapeutics GmbH
Bristol-Myers Squibb Co
Candel Therapeutics Inc
Cantex Pharmaceuticals Inc
Carina Biotech Pty Ltd
CARsgen Therapeutics Ltd
Cell Medicine Cooperation
Cellatoz Therapeutics Inc
CellCure
Celldex Therapeutics Inc
Cellestia Biotech AG
Cellis AG
Cellivery Therapeutics Inc
Cellworks Group Inc
Celros Biotech Co Ltd
Century Therapeutics Inc
Chemestmed OU
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chimeric Therapeutics Ltd
Chimerix Inc
Clarity Pharmaceuticals Ltd
Cloaked Therapeutics LLC
Clonz Biotech Pvt Ltd
CNS Pharmaceuticals Inc
Codiak BioSciences Inc
Cothera Bioscience Pty Ltd
Cotinga Pharmaceuticals Inc
Curative Biotechnology Inc
CureLab Oncology Inc
Curevac NV
Curigin Co Ltd
Curtana Pharmaceuticals Inc
Cynata Therapeutics Ltd
Cytix Inc
Cytodyn Inc
Cytonus Therapeutics Inc
Cytovia Holdings Inc
Daiichi Sankyo Co Ltd
Dalriada Therapeutics Inc
DEKK-TEC Inc
Denovo Biopharma LLC
DevaCell Inc
Diakonos Research Ltd
Diverse Biotech Inc
Divide and Conquer Ltd
DNAtrix Inc
DynamiCure Biotechnology LLC
Edison Oncology Holding Corp
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Elicera Therapeutics AB
Elpis Biopharmaceuticals Corp
ENB Therapeutics LLC
EnduRx Pharmaceuticals Inc
Enochian Biosciences Inc
EntreChem SL
Enveric Biosciences Inc
EpicentRx Inc
EpiDrugs Discovery
Epigene Therapeutics Inc
ERC Belgium SA
ERYTECH Pharma SA
Etirarx LLC
Eutilex Co Ltd
Ever Supreme Bio Technology Co Ltd
Everfront Biotech Inc
Evgen Pharma Plc
Exopharm Ltd
F. Hoffmann-La Roche Ltd
Falcon Therapeutics Inc
Felicitex Therapeutics Inc
Flag Therapeutics Inc
Flavocure Biotech LLC
Fore Biotherapeutics Inc
Fujifilm Holdings Corp
Galapagos NV
Gan & Lee Pharmaceuticals Co Ltd
Gedeon Richter Plc
Geneius Biotechnology Inc
Genenta Science SpA
Genentech USA Inc
Geneos Therapeutics Inc
Genexine Inc
Genisphere LLC
Genomefrontier Therapeutics Inc
Genor BioPharma Co Ltd
Genoscience Pharma
Gilead Sciences Inc
GlioCure SAS
Glycostem Therapeutics BV
GlyTherix Ltd
GSK plc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangxi Hebabiz Pharmaceutical Co Ltd
HaimBio Ltd
Hamlet Pharma AB
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Co Ltd
Hemispherian AS
HOX Therapeutics Ltd
Humanigen Inc
Hunan Siweikang Therapeutics Ltd
Hutchison MediPharma Ltd
i2 Pharmaceuticals Inc
Ibex Biosciences LLC
Immatics NV
Immix BioPharma Inc
ImmPACT Bio USA Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunitor Inc
ImmunityBio Inc
ImmunoAct Pvt Ltd
Immunomic Therapeutics Inc
Implicyte Inc
Imunon Inc
IMV Inc
Imvax Inc
IN8bio Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Ingenew Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
Inspirna Inc
Instituto Biomar SA
IntelliStem Technologies Inc
Intensity Therapeutics Inc
InterLeukin Combinatorial Therapies Inc
InteRNA Technologies BV
Invectys SA
Isarna Therapeutics GmbH
Istari Oncology Inc
ITM Isotope Technologies Munich SE
J Ints Bio Co Ltd
JenKem Technology Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Jubilant Therapeutics Inc
JW CreaGene Co Ltd
Kalgene Pharmaceuticals Inc
Kancera AB
Kartos Therapeutics Inc
Karus Therapeutics Ltd
Karyo Biologics LLC
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kidswell Bio Corp
Kintara Therapeutics Inc
Komipharm International Co Ltd
Kringle Pharma Inc
Lacerta Therapeutics Inc
Laminar Pharmaceuticals SA
Lantern Pharma Inc
Lauren Sciences LLC
LeadInvent Pharma Inc
Legend Biotech Corp
Lentigen Technology Inc
Liangjiang Medicine Co Ltd
Lin Bioscience Inc
Luminus Biosciences Inc
Lumos Pharma Inc
Luye Pharma Group Ltd
MacroGenics Inc
MAIA Biotechnology Inc
Matrix Biomed Inc
Medesis Pharma SA
Medical Guidance Systems LLC
Medicenna Therapeutics Corp
Medicon Pharmaceuticals Inc
Medisun Precision Medicine Ltd
MedPacto Inc
Mepsgene Co Ltd
Mercaptor Discoveries Inc
Merck & Co Inc
Merck KGaA
Meryx Inc
Metis Precision Medicine
MetVital Inc
MGC Pharmaceuticals Ltd
Midatech Pharma Plc
Millennium Pharmaceuticals Inc
MimiVax LLC
Mina Therapeutics Ltd
MiReven Pty Ltd
Molecular Targeting Technologies Inc
Moleculin Biotech Inc
Mustang Bio Inc
Mycenax Biotech Inc
Myeloid Therapeutics Inc
Myosin Therapeutics Inc
Myrio Therapeutics Pty Ltd
Nanjing Aimeifei Biomedical Technology Co Ltd
Nanjing CART Medical Technology Co Ltd
Nanjing KAEDI Biotech Inc
Nanocan Therapeutics Corp
NanoCarrier Co Ltd
Nanomerics Ltd
NanoPharmaceuticals LLC
Nascent Biotech Inc
NatureWise Biotech & Medicals Corp
NeoTX Therapeutics Ltd
Neuropore Therapies Inc
NewG Lab Pharma Inc
NGM Biopharmaceuticals Inc
NH TherAguix SAS
Northlake International LLC
Northwest Biotherapeutics Inc
Nostrum Biodiscovery SL
Novartis AG
Noxopharm Ltd
Nuvalent Inc
NuvOx Pharma LLC
Nyrada Inc
Oblato Inc
Ocean Biomedical Inc
OGD2 Pharma SAS
Oleolive LLC
Omniox Inc
Oncodesign SA
Oncolytics Biotech Inc
Onconova Therapeutics Inc
OncoResponse Inc
Oncorus Inc
OncoRx Pharmaceuticals Inc
Oncotelic Therapeutics Inc
Oncoteq AG
OncXerna Therapeutics Inc
OneChain Immunotherapeutics
Ono Pharmaceutical Co Ltd
Origenis GmbH
Orphelia Pharma SAS
Ossianix Inc
Otsuka Pharmaceutical Co Ltd
Ovensa Inc
Palisades Therapeutics
Parabon NanoLabs Inc
Pascal Biosciences Inc
Patrys Ltd
PENAO Pty Ltd
Peptomyc SL
Pfizer Inc
Phanes Therapeutics Inc
Pharma Mar SA
PharmAbcine Inc
PharmCADD Co Ltd
Philogen SpA
Phoenix Biotechnology Inc
Phost'IN SAS
Photolitec LLC
Photonamic GmbH & Co KG
Pinotbio Inc
Plex Pharmaceuticals Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
PolyPid Ltd
Praesidia Biotherapeutics Inc
Prelude Therapeutics Inc
Prescient Therapeutics Ltd
Preveceutical Medical Inc
Primevax Immuno Oncology Inc
PTC Therapeutics Inc
Puma Biotechnology Inc
QED Therapeutics Inc
Quadriga BioSciences Inc
Qualigen Therapeutics Inc
R-Pharm
Radiopharm Theranostics Ltd
Refuge Biotechnologies Inc
Regeneron Pharmaceuticals Inc
Reglagene Holding Inc
Regulus Therapeutics Inc
ReNeuron Group Plc
Ridgeline Therapeutics LLC
Rottapharm Biotech Srl
Rznomics Inc
Safe Save Medical Cell Sciences & Technology Co Ltd
Sagimet Biosciences Inc
Salarius Pharmaceuticals Inc
Sano Chemicals Inc
Sanofi
Sapience Therapeutics Inc
Sentinel Oncology Ltd
Serb SAS
Shanghai Escugen Biotechnology Co Ltd
Shanghai Henlius Biotech Inc
Shanghai HyaMab Biotech Co Ltd
Shanghai Novamab Biopharmaceuticals Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shenzhen BinDeBio Ltd
Shenzhen Zhenxing Pharmaceutical Technology
Shuttle Pharmaceuticals Inc
SideROS
SignPath Pharma Inc
Silenseed Ltd
Singh Biotechnology LLC
SixFold Bioscience Ltd
SK Life Science Inc
SL Bigen Co Ltd
SL VaxiGen Inc
Spectrum Pharmaceuticals Inc
Speer Medical Technologies LLC
STAT3 Therapeutics Inc
StemGen SpA
StemVax LLC
Suntec Medical (Taiwan) Inc
Susavion Biosciences Inc
Suzhou JiSheng Pharmaceutical Co Ltd
Suzhou Stainwei Biotech Inc
Synactix Pharmaceuticals Inc
Synchronicity Pharma Inc
Synergys Biotherapeutics Inc
SyntheX Inc
Tactical Therapeutics Inc
TAE Life Sciences LLC
Taiho Oncology Inc
Tango Therapeutics Inc
Targinta AB
TargTex SA
TC BioPharm Ltd
Telo Therapeutics Inc
Telomium SAS
The Palo Alto Research Center
TheraBiologics Inc
TheraBioPharma Inc
Theralase Technologies Inc
Therapeia GmbH & Co KG
Titan Pharmaceuticals Inc
TME Pharma AG
Tmunity Therapeutics Inc
Transcode Therapeutics Inc
Transtarget Inc
Trevarx Biomedical Inc
Triterpenoid Therapeutics Inc
Turning Point Therapeutics Inc
TVAX Biomedical Inc
Tyme Inc
U-Cell Therapeutics Pte Ltd
Up Therapeutics Inc
UTC Therapeutics Inc
Vault Pharma Inc
VBI Vaccines Inc
VCN Biosciences SL
Vect-Horus SAS
Verismo Therapeutics
Vigeo Therapeutics Inc
Vivace Therapeutics Inc
Voronoi Group
Vyro Bio Inc
Wayshine Biopharma Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
WindMIL Therapeutics Inc
WPD Pharmaceuticals Inc
Wuhan Binhui Biotechnology Co Ltd
X4 Pharmaceuticals Inc
Xequel Bio Inc
Xi'An Yufan Biotechnology Co Ltd
Xonovo Inc
Yooyoung Pharm Co Ltd
Yuhan Corp
Yumanity Therapeutics Inc
Zata Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
ZhongSheng BioTech Inc
Zumutor Biologics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glioblastoma Multiforme (GBM) – Overview

Glioblastoma Multiforme (GBM) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Glioblastoma Multiforme (GBM) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glioblastoma Multiforme (GBM) – Companies Involved in Therapeutics Development

Glioblastoma Multiforme (GBM) – Drug Profiles

Glioblastoma Multiforme (GBM) – Dormant Projects

Glioblastoma Multiforme (GBM) – Discontinued Products

Glioblastoma Multiforme (GBM) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Glioblastoma Multiforme (GBM), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Glioblastoma Multiforme (GBM) – Dormant Projects, 2022

Glioblastoma Multiforme (GBM) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Glioblastoma Multiforme (GBM), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more